Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma.

MLA

Scheiner, Bernhard, et al. “Efficacy and Safety of Immune Checkpoint Inhibitor Rechallenge in Individuals with Hepatocellular Carcinoma.” JHEP Reports : Innovation in Hepatology, vol. 5, no. 1, Oct. 2022, p. 100620. EBSCOhost, https://doi.org/10.1016/j.jhepr.2022.100620.

APA

Scheiner, B., Roessler, D., Phen, S., Lim, M., Pomej, K., Pressiani, T., Cammarota, A., Fründt, T. W., von Felden, J., Schulze, K., Himmelsbach, V., Finkelmeier, F., Deibel, A., Siebenhüner, A. R., Shmanko, K., Radu, P., Schwacha-Eipper, B., Ebert, M. P., Teufel, A., … Pinter, M. (2022). Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma. JHEP Reports : Innovation in Hepatology, 5(1), 100620. https://doi.org/10.1016/j.jhepr.2022.100620

Chicago

Scheiner, Bernhard, Daniel Roessler, Samuel Phen, Mir Lim, Katharina Pomej, Tiziana Pressiani, Antonella Cammarota, et al. 2022. “Efficacy and Safety of Immune Checkpoint Inhibitor Rechallenge in Individuals with Hepatocellular Carcinoma.” JHEP Reports : Innovation in Hepatology 5 (1): 100620. doi:10.1016/j.jhepr.2022.100620.